CN1230436A - Soluble recombined human bone formation protein 2 used in treating hemospoietic dysfunction and function damage - Google Patents
Soluble recombined human bone formation protein 2 used in treating hemospoietic dysfunction and function damage Download PDFInfo
- Publication number
- CN1230436A CN1230436A CN 98113048 CN98113048A CN1230436A CN 1230436 A CN1230436 A CN 1230436A CN 98113048 CN98113048 CN 98113048 CN 98113048 A CN98113048 A CN 98113048A CN 1230436 A CN1230436 A CN 1230436A
- Authority
- CN
- China
- Prior art keywords
- human bone
- bone morphogenetic
- bmp
- morphogenetic protein
- recombined human
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Abstract
The present invention includes the following steps: to utilize the chain reaction of reverse transcription polymerase to obtain the whole sequence and partial sequence of recombined human bone morphogenesis protein 2 (rhBMP-2) gene; to obtain the recombined expression products of rhBMP-2 through gene engineering means; to obtain soluble rhBMP-2 with biological activity through the purification of the expression products; and to inject proper amount of soluble rhBMP-2 through intramuscular or hypodermic injection to treat hemopoietic system diseases. Experiment shows that the present invention is superior to various clinically used hemopoiesis factors.
Description
The present invention relates to utilize genetic engineering means to prepare a kind of soluble recombined human bone morphogenetic protein(BMP) 2 (rhBMP-2) that is used for the treatment of hematopoietic disorder and damage.
The hemopoietic system damage that causes behind hemopoietic system dysfunction and functional defect and the radiation and chemotherapy is comparatively common clinically.Be applied to clinical various medicines and have now, as grain---effect such as M-CSF (GM-CSF), erythropoietin (EPO) is all relatively limited to, and can only stimulate a certain is blood cell proliferation.Common hematopoietic disorder or damage often relate to polyphyly even respectively are hemocyte, and then there is much still insurmountable at present problem in some multi-functional Hemopoietic factor because of it as interleukin (1L-3), can't be applied to clinical as toxic and side effects etc.People are to the research of bone morphogenetic protein(BMP) (BMP), mainly concentrated on the applied research that bone injury is repaired in the past, it is then studied seldom in the generation of hemopoietic system and the function aspect the reparation after disease of hematopoietic system and the damage, only limit to bone morphogenetic protein(BMP) 2 (BMP-2), bone morphogenetic protein(BMP) 4 (BMP-4) participates in the early stage hemopoietic system differentiation of fetal development, grows and induces dystopy bone marrow to form some preliminary observations of phenomenon when inducing the dystopy skeletonization.Its reason is that the recombination human bone shaping protein 2 who in the past utilized genetic engineering means to prepare all is insoluble, mainly shows its induced osteogenesis activity.Up to now, domestic and international still unmatchful bone morphogenetic protein(BMP) 2 is used for the research report of disease of hematopoietic system and injury in treating aspect.
The purpose of this invention is to provide a kind of soluble recombined human bone morphogenetic protein(BMP) 2 that is used for the treatment of hematopoietic disorder and damage.It has comprehensive and clear and definite therapeutic effect to hematopoietic disorder or damage, is better than the various placental extractses of present clinical practice.
In order to reach above-mentioned goal of the invention, technical scheme of the present invention realizes as follows: be used for the treatment of the soluble recombined human bone morphogenetic protein(BMP) 2 of hematopoietic disorder and damage, its step mainly comprises: 1. utilize inverse transcription polymerase chain reaction (RT-PCR) mode to obtain required Human Bone Morphogenetic Proteins-4 2 (hBMP-2) gene complete sequence and partial sequence; 2. utilize genetic engineering means to obtain various human bone morphogenetic protein(BMP) 2 recombination expression products; 3. the purification by expression product, or obtain to have the active soluble recombined human bone morphogenetic protein(BMP) 2 of good biological behind degeneration, renaturation and the purification; 4. with soluble recombined human bone morphogenetic protein(BMP) 2 muscle or the subcutaneous injection of suitable dosage, can bring into play therapeutical effect to dysplasia, functional defect, dysfunction and the injury repairing of hemopoietic system; Suitably the soluble recombined human bone morphogenetic protein(BMP) 2 of dosage can stimulate the various kinds of cell of In vitro culture, as the propagation and the differentiation of Interstitial cell, stromal cell, hematopoietic stem cell and hemopoietic forebody cell etc.
According to technique scheme, the described gene means of utilizing comprise the peptide section of utilizing various prokaryotic systems, Yeast system, fungal systems and eukaryotic system expressing human bone morphogenetic protein(BMP) 2 different lengths.
According to technique scheme, described Human Bone Morphogenetic Proteins-4's 2 gene complete sequences and partial sequence comprise mutant and with the fusant of other genes of interest.
Confirm by a large amount of cell in vitro experiments and zoopery, soluble recombined human bone morphogenetic protein(BMP) 2 has the hemopoietic of inducing activity, can both bring into play good therapeutical effect to hemopoietic system functional defect, dysplasia or dysfunction and injury repairing, therapeutic effect is clear and definite.The present invention compares with prior art, but have scale produce in enormous quantities, simple to operate, with short production cycle, output is high, cost is low, purity is high, activity is good, steady quality, characteristics safe in utilization.Can in clinical practice, open up wide use prospect.
The invention will be further described below in conjunction with concrete implementation method and experimental example.
Implementation method: the 1. acquisition of coding Human Bone Morphogenetic Proteins-4 2 (hBMP-2) total length and carbon teminal peptide gene: according to Human Bone Morphogenetic Proteins-4's 2 gene complete sequences of having delivered, polymerase chain reaction (PCR) primer of design amplification different length carbon teminal peptide section, the gene segment of different length such as amplification coding Human Bone Morphogenetic Proteins-4 2 total lengths and carbon teminal 244,219,192,173,141,114,102 aminoacid from the cDNA library; 2. the expression of coding Human Bone Morphogenetic Proteins-4's 2 total lengths and carbon teminal peptide fragment gene: genes of interest is cloned into carrier for expression of eukaryon pCDNA3, pBacPAK8 etc. and prokaryotic expression carrier pEC, pGC, pGEX-4T etc., transfection CHO cell and escherichia coli (E.coli) obtain the engineering cell of expressing human bone morphogenetic protein(BMP) 2; 3. purification of Human Bone Morphogenetic Proteins-4's 2 genetic engineered product (with degeneration, renaturation) and determination of activity: obtain eucaryon Human Bone Morphogenetic Proteins-4 2 expression products with multiple chromatography means through rationalization.E. coli expression product separates through inclusion body, and albuminous degeneration, renaturation, chromatography purification obtain soluble recombined human bone morphogenetic protein(BMP) 2 (rhBMP-2).The method of inducing the hemopoietic activity to utilize its medullary cell that can strengthen cultivation to form colony on soft agar of soluble recombined human bone morphogenetic protein(BMP) 2 is measured and is confirmed.
Experimental example 1: soluble recombined human bone morphogenetic protein(BMP) 2 (rhBMP-2) is used for the treatment of the application of hemopoietic type acute radiation disease: mice is behind the 7.5Gy radiation gamma, untreated animal is all dead in 10 days, and 2 groups of lumbar injection soluble recombined human bone morphogenetic protein(BMP), every Mus 0.5ug/ days, continuous use after 6 days survival rate reach 80%.To peripheral blood, spleen, bone marrow and grain---the inspection that macrophage colony forms shows that all treatment group hemopoietic system is recovered preferably.
Experimental example 2: soluble recombined human bone morphogenetic protein(BMP) 2 (rhBMP-2) is used for the treatment of the application of hemopoietic system damage disease after the radiotherapy: the rabbit of average weight 2kg with half lethal dose gamma-rays 7.5Gy irradiation, is formed the radiation-induced damage model.Treatment group subcutaneous injection soluble recombined human bone morphogenetic protein(BMP) 2, every rabbit 0.5ug/kg body weight, continuous use 6 days found that the hemopoietic system of damage can be repaired in 7～10 days.
Claims (3)
1. be used for the treatment of the soluble recombined human bone morphogenetic protein(BMP) 2 of hematopoietic disorder and damage, it is characterized in that: 1. utilize inverse transcription polymerase chain reaction (RT-PCR) mode to obtain required Human Bone Morphogenetic Proteins-4 2 (hBMP-2) gene complete sequence and partial sequence; 2. utilize genetic engineering means to obtain various human bone morphogenetic protein(BMP) 2 recombination expression products; 3. by the purification of this expression product, i.e. obtain to have bioactive soluble recombined human bone morphogenetic protein(BMP) 2 (rhBMP-2) after degeneration, the renaturation; 4. with recombination human bone shaping protein's 2 muscle or the subcutaneous injection of suitable dosage, can be to bringing into play therapeutical effect in dysplasia, functional defect or the dysfunction of hemopoietic system and the injury repairing; Suitably the soluble recombined human bone morphogenetic protein(BMP) 2 of dosage can stimulate the various kinds of cell of In vitro culture such as the propagation and the differentiation of Interstitial cell, stromal cell, hematopoietic stem cell and hemopoietic forebody cell etc.
2. according to the described soluble recombined human bone morphogenetic protein(BMP) 2 that is used for the treatment of hematopoietic disorder and damage of claim 1, it is characterized in that: the described gene means of utilizing comprise and utilize various prokaryotic systems, Yeast system, fungal systems and eukaryotic system to express the peptide section of Human Bone Morphogenetic Proteins-4's 2 different lengths.
3. according to claim 1 or the 2 described soluble recombined human bone morphogenetic protein(BMP) 2 that are used for the treatment of hematopoietic disorder and damage, it is characterized in that: described Human Bone Morphogenetic Proteins-4's 2 gene complete sequences and partial sequence comprise mutant and with the fusant of other genes of interest; Described soluble human bone morphogenetic protein(BMP) 2 comprises its deutero-various compound dosage forms release dosage form that eases up.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 98113048 CN1230436A (en) | 1998-12-15 | 1998-12-15 | Soluble recombined human bone formation protein 2 used in treating hemospoietic dysfunction and function damage |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN 98113048 CN1230436A (en) | 1998-12-15 | 1998-12-15 | Soluble recombined human bone formation protein 2 used in treating hemospoietic dysfunction and function damage |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN1230436A true CN1230436A (en) | 1999-10-06 |
Family
ID=5222831
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN 98113048 Pending CN1230436A (en) | 1998-12-15 | 1998-12-15 | Soluble recombined human bone formation protein 2 used in treating hemospoietic dysfunction and function damage |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN1230436A (en) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN100410371C (en) * | 2006-05-13 | 2008-08-13 | 暨南大学 | Expression method of recombination human bone formation protein-2 |
-
1998
- 1998-12-15 CN CN 98113048 patent/CN1230436A/en active Pending
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN100410371C (en) * | 2006-05-13 | 2008-08-13 | 暨南大学 | Expression method of recombination human bone formation protein-2 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR960013601B1 (en) | Production and use of il-6 | |
| EP0272703B2 (en) | Novel polypeptide | |
| EP0494268B1 (en) | Method for inhibiting growth of stem cells | |
| AU676891B2 (en) | Pharmaceutical containing the P40 subunit of interleukin 12 | |
| KR900701824A (en) | Compositions and methods for treating or preventing animal infections | |
| IE54371B1 (en) | Human immune interferon and its production by recombinant dna technology | |
| DE60208692T2 (en) | INTERLEUKIN -18 MUTANT PROTEINS, THEIR PREPARATION AND USE | |
| EP0170204B1 (en) | Genetic sequences, type i interferon peptide coded by them, and these organisms producing the same | |
| WO2007107882A2 (en) | Method for purifying granulocyte-colony stimulating factor | |
| CN1230436A (en) | Soluble recombined human bone formation protein 2 used in treating hemospoietic dysfunction and function damage | |
| ES2229250T3 (en) | PROCEDURE FOR THE USE OF THE PA-ADH PROMOTING SYSTEM IN A YEAST FOR THE BIIOTECHNOLOGICAL PRODUCTION OF HETEROLOGICAL PROTEINS IN HIGH PERFORMANCES. | |
| CN100398557C (en) | Polypeptide for inhibition of angiogenesis and method for preparing same and use thereof | |
| CN100435848C (en) | Gene treatment to raise feed efficiency and promote growth of farm animal | |
| CN1207305C (en) | Preparing process and application of recombined human interleukin-11 | |
| EP0174999B1 (en) | Method for improving expression and method thereto | |
| WO2023246938A1 (en) | Therapeutic mrna for solid tumors and use thereof | |
| CN1273976A (en) | Process for preparing recombined morphogenetic protein (rhOP-1) of human bone | |
| CN101812135B (en) | Fusion protein with high-efficient platelet-increasing role and preparation method thereof | |
| CN1234727C (en) | Human thymosin alpha protogene mutant synthesis, expression and use | |
| EP2195338B1 (en) | N-terminal modified interferon-alpha | |
| CN1328382C (en) | Recombination expression method for black porgy tumor necrosis factor alph gene | |
| AU2016342210A1 (en) | Method for producing a recombinant protein with reduced impurities | |
| CN101445560A (en) | Method for preparing fusion protein used for livestock and poultry | |
| CN1259337C (en) | Synthesis, expression, preparation and application for human parathyroid hormone gene mutant | |
| CN101153278A (en) | Method for producing recombined human granular leukocyte colony stimulating factor |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C02 | Deemed withdrawal of patent application after publication (patent law 2001) | ||
| WD01 | Invention patent application deemed withdrawn after publication | ||
| REG | Reference to a national code |
Ref country code: HK Ref legal event code: GR Ref document number: 1066544 Country of ref document: HK |